FDA Warns 30 Telehealth Firms Over Misleading Compounded GLP-1 Ads

This is the second group of warning letters the FDA has sent to telehealth firms since September 2025.

Signage outside the Food and Drug Administration (FDA) headquarters in White Oak, Md., on Aug. 29, 2020. Andrew Kelly/Reuters

The Food and Drug Administration (FDA) has issued 30 warning letters to companies that the agency said are making false or misleading claims about compounded GLP-1 products being offered on their websites.

In its March 3 announcement, the FDA said that compounded drugs are not FDA-approved, which means the agency does not review their safety, effectiveness, or quality before they are marketed to the public. Compounded drugs are different from generic drugs, which are approved by the FDA.